TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Flare-rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Ibrutinib dose modification following tisagenlecleucel infusion
Endpoint domain: Adverse events/effects
Primary endpoint: SF-36 quality of life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oswestry functional disorder questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum End-tidal carbon dioxide (ETCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absence of significant drug related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: acute myocarditis occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: COVID19 lung lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scores on the Hamilton Depression Rating Scale for Seasonal Affective Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Remission Status on the Hamilton Depression Rating Scale for Seasonal Affective Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Forearm blood flow ratio and/or absolute flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in gambling symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Registration on the national waiting list
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Active and trained innate immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of participants with systemic drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Troponin I (TnI) Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to local or distant failure
Endpoint domain: Mortality/survival
Primary endpoint: Rate of viral breakthrough during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of E7107
Endpoint domain: Adverse events/effects
Primary endpoint: Incremental area under the serum acetate response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ER Visits and Hospital Admission Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ECOG Performance Status at End Of Treatment Visit (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit rate (cure or improvement of hypertension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time on treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Eating Inventory - Internal Disinhibition subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glycosylated haemoglobin evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Assessed for Blood Pressure Goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in number of urgency episodes per 24 hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 3 year disease-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Genotype for resistance determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory infection symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Premenstrual Syndrome Scale (PMSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in maternal State-Trait Anxiety Index scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in maternal Beck Depression Index II scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in maternal Brief Cope Inventory survey scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in maternal PedsQL Family Impact Module survey scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of Participants With Negative Hepatitis D Virus Ribonucleic Acid (HDV RNA) at Week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 7-day point prevalence quit rate of smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental developmental index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Corneal lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants completing the FIT test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Profile of Mood States Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of drug type and concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between drug concentration and VOC concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Location of Posterior Denture Tooth Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients meeting VALUE trial criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium handling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continued use of the MapMySmoke App
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Subjects With Evidence of Pancreatic Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: presence of NK lymphocytes expressing CD86 and HLA-DR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acquisition of sufficient data for perfusion analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clotting time (CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic (PK) profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal fermentation end products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient's Oral Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methacholine sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Yearly all-cause mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: PSRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of inflammatory granulomas
Endpoint domain: Adverse events/effects
Primary endpoint: Excision perfection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks Post Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in Patients Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tidal Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔMAP (Mean Arterial Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chemical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of histological pathological differential diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of immunohistochemical pathological differential diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of molecular pathological differential diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with poor prognosis and high levels of XCL1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with poor prognosis and high levels of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: bleeding stops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Motor Score-4 component (TMS) of the UHDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics profile of lesinurad
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time on vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of telomeres
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Received Influenza Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual and semi-quantitative evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive Fungal Infection (IFI)
Endpoint domain: Adverse events/effects
Primary endpoint: Bacteraemia
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Pressure Systolic and Diastolic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term prognosis
Endpoint domain: Mortality/survival
Primary endpoint: Stimulated ln(IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stimulated ln(TNF-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of tumor burden assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Airflow decline (AFD)-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline muscle strength at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline pain intensity at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of induration or redness in TB patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Size of induration or redness in non-TB subjects with lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of buccal vs vaginal administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With PASI 75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of fertility preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Safety of fertility preservation
Endpoint domain: Adverse events/effects
Primary endpoint: Glycemic deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of undescended testis (cryptorchidism)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Response to Moderate-dose Cyclophosphamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: anesthesia satisfaction rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Peer Navigation Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Verbal fluency test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Status (Success/Failure) of Contact Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence / Absence of DOAC Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance measured by SDMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance measured by Cogstate Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Subjective measures of Sleep quality: Pittsburgh Sleep Quality Index Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Polysomnography: objective changes in sleep onset latency (SOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polysomnography: objective changes in wake after sleep onset (WASO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Opiate Withdrawal Scale (COWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Related Emergency Department (ED) Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Treatment Engagement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Pharmacodynamics measured by Visual Analogue Scales (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurobehavioral Performance Summary Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley Scales of Infant and Toddler Development Third Edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Clinically Relevant Postoperative Pancreatic Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Spatial and temporal treatment response to radiation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of hospital Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: incident adverse event reports
Endpoint domain: Adverse events/effects
Primary endpoint: vital sign measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: electrocardiograms (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Foot pain subscale of the Foot Health Status Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Exclusive breastfeeding among children aged 0-5.9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Minimum dietary diversity among children aged 6-23.9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Minimum meal frequency of (semi) solid or soft foods among children aged 6-23.9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Number of Participants That Used and Returned Their Self-sampler Kit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MOCA Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma Inflammatory Mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Best Corrected Visual Acuity for Distance Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fixation Stability (Bivariate contour ellipse area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With no Disease Activity at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elastic properties of a forming clot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of the combination (Copanlisib + Cetuximab)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thirst intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Burning or Pulling Sensations in Chest/Device Pocket During MRI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Potentially Lethal/Previously Non-diagnosed Arrhythmias During MRI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Injury/Death Related to MRI Device Malfunction/Failure
Endpoint domain: Mortality/survival
Primary endpoint: Diaper weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Composite Efficacy Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The number of damaged points on HVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HVC hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[0-24h]) of Rilpivirine 12.5 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[0-24h]) of Rilpivirine 15 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[0-24h]) of Rilpivirine 25 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Days of Any Substance Use for Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Number of Drinking Days for Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-m backwards walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berg balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients on demand replacement therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with low or high responding inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of hypernatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of hypernatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Steps Completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Subjective Distress (Klorman Spider Phobia Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Subjective Distress (Syzmanski Fear of Spiders Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite of Major adverse cardiac events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in appetite and eating behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual Muscle Testing in 24 Muscles (MMT24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Creatine Kinase (CK) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in composite IMU sensor based metrology index (IMU-ASMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath Hold Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subject-reported Dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of Pet-CT scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of Pemetrexed
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Radiofrequency Ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Eradication Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Kaihani Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of lumateperone and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum observed plasma concentration (Tmax) of lumateperone and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes